Item 2.02 Results of Operations and Financial Condition.

On January 4, 2022, Allena Pharmaceuticals, Inc. (the "Company") issued a press release (the "Press Release") providing an update on its lead clinical programs and strategic outlook, which Press Release included the Company's approximate cash and cash equivalents for the year ended December 31, 2021 (the "Financial Information"). The Financial Information is unaudited and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2021 and its results of operations for the three or twelve months ended December 31, 2021. A copy of the Press Release is furnished herewith as Exhibit 99.1.

The Financial Information set forth in Item 2.01 and Exhibit 99.1 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 8.01 Other Events.

On January 4, 2022, the Company issued the Press Release providing an update on its lead clinical programs and strategic outlook.

A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit
  No.       Description

99.1          Press Release of Allena Pharmaceuticals, Inc., dated January 4,
            2022.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses